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Abstract
Background. When vaccination depends on injection, it is plausible that the blood-injection-
injury cluster of fears may contribute to hesitancy. Our primary aim was to estimate in the UK
adult population the proportion of COVID-19 vaccine hesitancy explained by blood-injec-
tion-injury fears.
Methods. In total, 15 014 UK adults, quota sampled to match the population for age, gender,
ethnicity, income and region, took part (19 January–5 February 2021) in a non-probability
online survey. The Oxford COVID-19 Vaccine Hesitancy Scale assessed intent to be vacci-
nated. Two scales (Specific Phobia Scale-blood-injection-injury phobia and Medical Fear
Survey–injections and blood subscale) assessed blood-injection-injury fears. Four items
from these scales were used to create a factor score specifically for injection fears.
Results. In total, 3927 (26.2%) screened positive for blood-injection-injury phobia.
Individuals screening positive (22.0%) were more likely to report COVID-19 vaccine hesitancy
compared to individuals screening negative (11.5%), odds ratio = 2.18, 95% confidence inter-
val (CI) 1.97–2.40, p < 0.001. The population attributable fraction (PAF) indicated that if
blood-injection-injury phobia were absent then this may prevent 11.5% of all instances of vac-
cine hesitancy, AF = 0.11; 95% CI 0.09–0.14, p < 0.001. COVID-19 vaccine hesitancy was asso-
ciated with higher scores on the Specific Phobia Scale, r = 0.22, p < 0.001, Medical Fear Survey,
r = 0.23, p = <0.001 and injection fears, r = 0.25, p < 0.001. Injection fears were higher in youth
and in Black and Asian ethnic groups, and explained a small degree of why vaccine hesitancy
is higher in these groups.
Conclusions. Across the adult population, blood-injection-injury fears may explain approxi-
mately 10% of cases of COVID-19 vaccine hesitancy. Addressing such fears will likely improve
the effectiveness of vaccination programmes.
Introduction
Vaccination is now a key global public health intervention to combat the severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2) pandemic. A variable proportion of the popula-
tion in each country will seek to delay or avoid being vaccinated, thereby limiting the success
of vaccination programmes. In the Oxford Coronavirus Explanations, Attitudes, and
Narratives Survey II (OCEANS-II), key factors associated with vaccine hesitancy in the UK
population were lower perception of risk from the virus, less awareness of the collective ben-
efits of vaccination, doubts about the efficacy of vaccination and worry about potential side
effects, particularly in the context of the rapid development and testing of the vaccines
(Freeman et al., 2020). In subsequent qualitative interviews, participants raised an issue that
had not been assessed in the survey: anxiety about injections. Fears about injection in the
short term might prevent the long-term benefits of vaccination. In children, adolescents
and adults, fear of injection falls within the unitary specific phobia subtype of
blood-injection-injury fears (Kendler, Aggen, Werner, & Fried, 2020; Loken, Hettema,
Aggen, & Kendler, 2014; Muris, Schmidt, & Merckelbach, 1999; Wenzel & Holt, 2003).
This is persistent excessive fear of blood, needles or invasive medical procedures, leading to
avoidance or endurance with intense anxiety. Uniquely among anxiety disorders, part of the
typical response pattern for this phobia is a drop in heart rate and
blood pressure leading to fainting. A fear of fainting may cause
great reluctance to join a line of peoplewaiting for a vaccine injection.
In our latest UK survey (Freeman et al., 2021), we therefore included
assessment of blood-injection-injury fears in order to determine the
degree to which they may be a factor in hesitancy about COVID-19
vaccination, which currently depends on injection.
There is a spectrum of severity of blood-injection-injury fears
in the general population, with heritability estimated at approxi-
mately 40% (Van Houtem et al., 2013). Determined by diagnostic
interview, lifetime prevalence of blood-injection-injury phobia in
the adult population is approximately 3–4% (Stinson et al., 2007;
Wardenaar et al., 2017). Rates are higher in women and in those
of younger age. Self-identified fear of needles is much more com-
mon. One convenience sample study found that over 20% of par-
ents and over 60% of children reported a fear of needles. Such
fears were identified as the primary reason for immunisation non-
compliance for 7% of parents and 8% of children (Taddio et al.,
2012). Fear of injection has been cited by both the general public
and health professionals as a reason for vaccination refusal, including
for influenza, tetanusandpneumococcal infections (Johnson,Nichol,
& Lipczynski, 2008; Yaqub, Castle-Clarke, Sevdalis, & Chataway,
2014). In a US survey conducted in June 2020, 11.8% of those who
were hesitant about COVID-19 vaccination reported that a reason
was a dislike of needles and injections (Ruiz & Bell, 2021). A higher
proportion (43.8%) identified fearof dangerous side effects as the rea-
son. In aUS studyof 9000 older adults conducted inNovember 2020,
1.7%were concerned about receiving aCOVID-19 vaccine because of
a fear of needles (Nikolovski et al., 2021). These studies suggest that,
although fearof injection is not the dominant reason for vaccine hesi-
tancy, it may be a contributory factor.
Our primary objective in this study was to determine the
degree to which blood-injection-injury fears may explain
COVID-19 vaccine hesitancy in the UK adult population. We
also set out to estimate the prevalence of significant blood-
injection-injury fears in the UK adult population. Furthermore,
we wanted to test the extent to which injection fears may account
for socio-demographic (age, gender, ethnicity and income) differ-
ences in COVID-19 vaccine hesitancy. Rather than merely asking
a single question about fear of needles, we used established assess-
ments. Our focus was on self-report, rather than diagnostic inter-
view, since it is likely to be subjective thoughts and feelings across
the spectrum of fear of injection that may have an impact regard-
less of whether they match diagnostic criteria. In a large survey of
the adult general population, we included a self-report assessment
of blood-injection-injury fears that can be used as a screening tool
for the potential presence of a phobia. To validate results, we
included an additional blood-injection fears questionnaire. We
expected blood-injection-injury fears to explain a small amount of
variance in vaccine hesitancy across the population. However, indivi-
duals with pronounced fears would be substantially more likely to be
hesitant about taking a vaccine. We also hypothesised that injection
fears may help explain (i.e. partially mediate) why vaccine hesitancy
is somewhat higher in particular demographic groups (younger age,
females, ethnic minority groups and lower income).
Methods
Participants
Oxford Coronavirus Explanations, Attitudes, and Narratives
Survey (OCEANS) III (Freeman et al., 2021) is an online survey
with a quota sampled UK participant group of 15 014 adults
(18+ years old), conducted from 19 January 2021 to the 5
February 2021 via a market research company, Lucid. The quotas
were based on UK Office for National Statistics population esti-
mate data for gender, age, ethnicity, income and region. We did
not wish to focus in this study only on those who had not been
vaccinated by a particular point in time, since such results
would be less generalisable, COVID-19 vaccination is highly
unlikely to be a ‘one off’ event (there are two doses and it is likely
to need renewal), and people who have been vaccinated still influ-
ence the rest of the population. Invited respondents did not know
the topic of the survey before provisional agreement to complete
it. They were simply told that there was a new survey and
informed of the time period for it to be completed. Only after
agreeing to participate did they see the online introduction.
There was no mention of phobias in the rationale for the study
provided, which was ‘There are now approved vaccines for
COVID-19 that will be rolled out in the UK over the coming
months. We want to learn about people’s views about vaccination
for COVID-19. In particular, we want to find out how many peo-
ple would or would not wish to be vaccinated and the reasons
behind their decision’. OCEANS-III was approved by the
University of Oxford Central University Research Ethics
Committee, and all participants provided informed consent
online.
Assessments
Initial vaccine hesitancy question
After agreeing to take part, participants completed a single ques-
tion: ‘If the vaccine was available at my GP surgery I would: 1. Get
it as soon as possible/2. Get it when I have time/3. Delay getting
it/4. Avoid getting it for as long as possible/5. Never get it/6. Don’t
know’. This question was found in our OCEANS-II study to have
the highest loading (0.95) on the COVID-19 vaccine hesitancy
latent factor but for that precise reason was not included in the
primary outcome measure (see Freeman et al., 2020 supplemen-
tary materials).
Oxford COVID-19 Vaccine Hesitancy Scale (Freeman et al., 2020)
Seven items [e.g. ‘Would you take a COVID-19 vaccine (approved
for use in the UK) if offered?’] are rated on item specific response
options (Saris, Krosnick, Revilla, & Shae, 2010), coded from 1 to
5. A ‘Don’t know’ option is also provided, which is excluded from
scoring. Higher scores indicate a higher level of vaccine hesitancy.
In the current study the Cronbach’s alpha of the scale was 0.97
(N = 15 014).
Specific Phobia Scale – blood-injection-injury
(Ovanessian et al., 2019)
This is a self-report screening scale for different types of specific
phobia based on the DSM-V criteria (APA, 2013). We used the 14
items assessing blood-injection-injury phobia. Each item (e.g.
‘Watching someone else get an injection’, ‘Getting minor surgery’,
‘Giving blood’ and ‘Receiving an injection’) is rated on a 5 point
rating scale for the degree of fear triggered [0 (no fear) to 4
(extreme fear)]. Scores on the subscale can range from 0 to 56,
with higher scores indicating a higher level of fear. A score of
20 or higher indicates the possible presence of a blood-injection-
-injury specific phobia (Ovanessian et al., 2019). In the current
study, the Cronbach’s alpha of the scale was 0.94 (N = 15 014).
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Medical fear survey – short version – injections and blood
(Olatunji et al., 2012)
Each of the four items [e.g. ‘Receiving a hypodermic (i.e. into the
skin) injection in the arm’, ‘Having blood drawn from your arm’]
is rated on a 4-point rating scale (0 = no fear to 3 = intense fear)
for the degree of fear provoked. Scores can range from 0 to 12,
with higher scores indicating greater fear. In the current study,
the Cronbach’s alpha of the scale was 0.90 (N = 15 014).
Injection fears
We also created from the two scales a factor score specifically for
injection fears, using the four items about injection [‘Watching
someone else get an injection’, ‘Receiving an injection’,
‘Receiving a hypodermic (i.e. into the skin) injection in the
arm’, ‘Seeing someone receiving an injection in the arm’].
Higher scores indicate greater fear of injection.
Statistical analysis plan
Statistical analyses were carried out in the R software environment
for statistical computing and graphics, Version 4.0.3.
Structural equation modelling (SEM) was used to evaluate the
factorial structure of the Oxford COVID-19 Vaccine Hesitancy
Scale, Specific Phobia Scale, Medical Fear Survey and the com-
bined four items measuring fear of injection, and to assess the
potential mediation effect of fear of injection for associations
between vaccine hesitancy and demographic factors. SEM is a col-
lection of statistical techniques composed of two parts. The first
part is the confirmatory measurement model, also known as the
confirmatory factor analysis (CFA), which estimates the relations
among latent constructs and their observed indicators. We
assessed the measurement models of the existing and new injec-
tion fear scale based on factor loadings, inter-correlation between
factors and several goodness-of-fit indices to ensure appropriate
specification. The second part is the structural model, which esti-
mates the relations among constructs (Kline, 2015). This combin-
ation allows the elimination of unreliability of measurement in the
models and can be used to make assumptions about how latent
constructs derived from observed variables are associated with
each other. The mediation analysis was also conducted under
the SEM framework and the advantages of such an approach
are discussed in Gunzler, Chen, Wu, and Zhang (2013).
With non-normal distributions and missing values within the
data, which in this case is considered either missing completely at
random or missing at random due to test design (Little & Rubin,
2019; Rubin, 1976), we utilised the full information maximum
likelihood estimation procedure with robust (Huber–White)
standard errors and a scaled test statistic to estimate the SEMs,
which has been described as a more efficient and less biased
approach than other ad hoc missing data techniques (Enders,
2001; Enders & Bandalos, 2001). The SEM supports the data
when the root mean square error of approximation (RMSEA)
and standardised root mean square residual (SRMR) are <0.08
(Kline, 2005). Additional fit indices included the comparative fit
index (CFI) and Tucker–Lewis Index (TLI), all of which should
exceed 0.90 (Kline, 2015), with RMSEA < 0.06, and CFI and
TLI > 0.95 indicating good model data fit (Hu & Bentler, 1999).
The confidence intervals (CIs) of the indirect effects in the media-
tional model using SEM were tested using a Monte Carlo method
with 20 000 replications as described by MacKinnon, Lockwood,
and Williams (2004). The Holm method was used to adjust the
p values in the mediational model using SEM to control the type
I error rate due to multiple comparisons (Holm, 1979). The lavaan
and the semTools R packages were used to conduct the SEM ana-
lyses (Jorgensen, Pornprasertmanit, Schoemann, & Rosseel, 2020;
Rosseel, 2012).
We used the population attributable fraction (PAF) to evaluate
vaccine hesitancy due to blood-injection-injury phobia. A histor-
ical review of the PAF is described by Poole (2015). The general
idea of PAF is to understand the proportion of unfavourable out-
comes that would have been prevented if the exposure of interest
was eliminated from the population (Levin, 1953). Analysis of
PAF was conducted using the AF R package (Dahlqwist,
Zetterqvist, Pawitan, & Sjölander, 2016). We dichotomised (1, 2
= no hesitancy, 3, 4, 5 = hesitancy) the single vaccine hesitancy
item that opened the survey (‘If the vaccine was available at my
GP surgery I would…’). Participants who answered 6 (‘don’t
know’) were defined as missing and excluded from the analysis.
The presence or absence of having a blood-injection-injury pho-
bia was calculated based on the total score of the Specific Phobia
Scale. Blood-injection-injury phobia was used as the exposure
variable and was dichotomised according to the recommended
cut-offs by Ovanessian et al. (2019). We used a logistic regression
model to first estimate the log odds of vaccine hesitancy levels
based on the presence of a phobia and included demographic
associations (age, ethnicity and gender) as confounding controls.
These demographic characteristics were known to be significant
predictors as reported in OCEANS-II (Freeman et al., 2020).
The beta coefficient estimates from the logistic regression model
were then used to estimate the adjusted PAF with the formula
described by Dahlqwist et al. (2016). The adjusted PAF was calcu-
lated as the proportion of vaccine hesitancy in the population that
is attributable to blood-injection-injury phobia (i.e. the propor-
tion of cases that might be prevented in the population if the
exposure variable was eliminated), after accounting for demo-
graphic associations. The standard errors were estimated using
the sandwich formula with the delta method (Greenland &
Drescher, 1993; Sjölander & Vansteelandt, 2011).
Results
A summary of the socio-demographic characteristics of the parti-
cipants is provided in Table 1. For the initial vaccine hesitancy
question – ‘If the vaccine was available at my GP surgery’ – 11
012 (73.3%) individuals reported that they would get it as soon
as possible, 1451 (9.7%) reported that that they would get it
when they have time, 672 (4.5%) reported that they would delay
getting it, 771 (5.1%) reported that they would avoid getting it
for as long as possible, and 632 (4.2%) said they would never
get it. In total, 476 (3.2%) said that they did not know. Hence,
2075 (13.8%) participants were classed as hesitant (scoring 3, 4
or 5).
Prevalence of blood-injection-injury fears
There was a high correlation between fears as assessed with the
Specific Phobia Scale and Medical Fears Survey, r = 0.81, p <
0.001, n = 15 014. The injection factor score correlated highly
with the Specific Phobia Scale score, r = 0.89, p < 0.001, n = 15
014 and Medical Fears Survey score, r = 0.92, p < 0.001, n = 15
014. The mean score of the participant group on the specific pho-
bia scale was 13.19, S.D. = 11.38, n = 15 014. In total, 3927 (26.2%)
screened positive for a specific blood-injection-injury phobia and
11 097 (73.8%) screened negative.
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Table 1. Socio-demographic information (N = 15 014)
Mean (S.D.)/n (%)








Gender: male; female; non-binary; prefer not say 7257 (48.3%); 7695 (51.3%);
41 (0.3%); 21 (0.1%)
Ethnicity
White
English/Welsh/Scottish/Northern Irish/British 11 988 (79.8%)
Irish 173 (1.2%)
Gypsy or Irish Traveller 44 (0.3%)
Any other White background 559 (3.7%)
Mixed/multiple ethnic groups
White and Black Caribbean 136 (0.9%)
White and Black African 54 (0.4%)
White and Asian 128 (0.9%)










Any other Black/African/Caribbean background 43 (0.3%)
Other ethnic group
Arab 61 (0.4%)
Any other ethnic group 60 (0.4%)
Marital status
Single 4626 (30.8%)




Prefer not to say 111 (0.7%)
Highest level of education
No qualifications 952 (6.4%)
(Continued )
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Table 1. (Continued.)
Mean (S.D.)/n (%)
GCSEs grades A*–C (or equivalent) 4148 (27.6%)
AS Levels (or equivalent) 621 (4.1%)
A Levels (or equivalent) 4068 (27.1%)
Certificate of higher education (e.g. BA, BSc, or equivalent) 3947 (26.3%)
Post graduate qualifications (e.g. MA, MSc, PhD, DPhil) 1276 (8.5%)
Total household income
Less than £15 000 2348 (15.6%)
£15 000–19 999 1441 (9.6%)
£20 000–29 999 2768 (18.4%)
£30 000–39 999 2231 (14.9%)
£40 000–49 999 1584 (10.6%)
£50 000–59 999 1117 (7.4%)
£60 000–69 999 753 (5.0%)
£70 000–99 999 1049 (7.0%)
£100 000–149 999 539 (3.6%)
£150 000 and above 224 (1.5%)
Prefer not to say 960 (6.4%)
Housing situation
Rented from council 2382 (15.9%)




North East 636 (4.2%)
North West 1621 (10.8%)
Yorkshire and the Humber 1205 (8.0%)
East Midlands 1084 (7.2%)
West Midlands 1373 (9.1%)
East 1205 (8.0%)
London 1978 (13.2%)
South East 2177 (14.5%)
South West 1282 (8.5%)
Wales 750 (5.0%)
Scotland 1293 (8.6%)
Northern Island 410 (2.7%)
Pre-coronavirus employment status
Unemployed 1168 (7.8%)
Employed full-time 6315 (42.1%)







Creation of factor scores
Participants who had four or more missing items (i.e. answered
don’t know to over half the items) on the Oxford COVID-19
Vaccine Hesitancy Scale were removed from further analysis.
This resulted in a sample size of 14 820 individuals, which was
used for the CFA models. The CFA model for the Oxford
COVID-19 Vaccine Hesitancy Scale indicated an excellent
model fit (χ2 = 1112.84, df = 14, p < 0.001, CFI = 0.98, TLI =
0.97, RMSEA = 0.07, SRMR = 0.01). The initial CFA model indi-
cated that the 14-item Specific Phobia Scale was unsatisfactory
(χ2 = 11 328.93, df = 77, p < 0.001, RMSEA = 0.10, SRMR = 0.05,
CFI = 0.86, TLI = 0.83). Therefore, in a post-hoc analysis, we eval-
uated the model adequacy based on the modification index (MI).
MI is an estimate of the amount of chi-square which would be
reduced if a parameter was added or the restriction of a specific
parameter was removed in the CFA model (Sörbom, 1989).
Specifically, we investigated MIs of correlated measurement errors
between given pairs of items. Freely estimating covariances of cor-
related measurement errors with high MI results in a substantial
decrease in the chi-square, thereby increasing model fit. However,
the use of correlated measurement errors comes at an expense of
theoretical accuracy since the covariance of the error term is from
at least one unknown common source (Fornell, 1983; Gerbing &
Anderson, 1984). It indicates that the specific pair of items has
unexplained common sources of variance that are not captured
by the latent variable. Given that the addition of the correlated
measurement errors does not improve the interpretation of the
model substantially, we instead used an alternative strategy,
which was to remove one of the paired items that displayed
high MI. We re-ran the analysis after the removal of each item
to inspect the model’s goodness-of-fit, which resulted in four
items being removed (item 3, 8, 10, 14). The final model indicated
acceptable goodness of fit results (χ2 = 2831.13, df = 35, p < 0.001,
CFI = 0.93, TLI = 0.92, RMSEA = 0.07, SRMR = 0.04). The CFA
model for the Medical Fear Survey indicated an excellent model
fit (χ2 = 187.50, df = 2, p < 0.001, CFI = 0.99, TLI = 0.96,
RMSEA = 0.08, SRMR = 0.02). The CFA model for the four-item
injection fears subscale indicated an excellent model fit (χ2 =





Yes, a positive test 980 (6.5%)
No, a negative test 4519 (30.1%)
May have had it but not been tested 1620 (10.8%)
Not had it but not been tested 7695 (51.3%)
Other 200 (1.3%)
Risk for severe COVID-19 course
Low risk 8608 (57.3%)
Moderate risk 4528 (30.2%)
Very high risk 1264 (8.4%)
Do not know 614 (4.1%)
Vaccinated for COVID-19
No 13 139 (87.5%)
Yes, because in vulnerable group 806 (5.4%)
Yes, because in keyworker group 770 (5.1%)
Yes, for another reason 291 (1.5%)
Do not know 80 (0.5%)
Table 2. Socio-demographic information for mediation analysis (N = 14 149)
Demographic group Group breakdown Sample size (n)
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Associations of blood-injection-injury fears and vaccine
hesitancy
The Oxford COVID-19 Vaccine Hesitancy Scale factor score
correlated positively with the Specific Phobia Scale factor score,
0.22, p < 0.001, n = 14 820; the Medical Fear Survey factor
score, r = 0.23, p < 0.001, n = 14 820; and the injection fears factor
score, r = 0.25, p < 0.001, n = 14 820. (In a sensitivity analysis, the
size of the associations was unchanged when controlling for
condition in the OCEANS-III trial.) The individuals screening
Table 3. Mediation results using SEM
Effect S.E. Lower CI Upper CI β Adjusted p value
(Relative) effect of IV on mediator (fear of injection)
Age −0.015 0.000 −0.016 −0.015 −0.344 0.003
Black 0.208 0.040 0.129 0.287 0.048 0.003
White Other 0.140 0.055 0.032 0.248 0.026 0.132
Other mixed background −0.005 0.077 −0.156 0.146 −0.001 1.000
Asian 0.168 0.029 0.110 0.225 0.054 0.003
Other background 0.160 0.080 0.003 0.317 0.018 0.450
20k to 40k −0.033 0.017 −0.067 0.001 −0.020 0.450
41k to 60k −0.059 0.020 −0.099 −0.019 −0.029 0.060
>60k −0.096 0.021 −0.137 −0.055 −0.047 0.003
Prefer not to say income 0.003 0.032 −0.060 0.065 0.001 1.000
Gender 0.038 0.013 0.013 0.064 0.024 0.060
Unique effect of mediator on outcome (hesitancy score)
Fear of injection 0.203 0.013 0.177 0.229 0.166 0.003
(Relative) indirect effect
Age −0.003 0.000 −0.004a −0.003a −0.057 0.003
Black and fear of injection 0.042 0.009 0.026a 0.059a 0.008 0.003
White other and fear of injection 0.028 0.011 0.006a 0.051a 0.004 0.132
Other mixed background and fear of injection −0.001 0.016 −0.031a 0.030a 0.000 1.000
Asian and fear of injection 0.034 0.006 0.022a 0.047a 0.009 0.003
Other background and fear of injection 0.032 0.016 0.001a 0.065a 0.003 0.450
Income between 20k to 40k and fear of injection −0.007 0.004 −0.014a 0.000a −0.003 0.450
Income between 41k to 60k and fear of injection −0.012 0.004 −0.020a −0.004a −0.005 0.060
Income >60k and fear of injection −0.020 0.004 −0.029a −0.011a −0.008 0.003
(Relative) direct effect of IV on outcome (hesitancy score)
Age −0.013 0.001 −0.014 −0.012 −0.241 0.003
Black 0.700 0.053 0.595 0.805 0.131 0.003
White other 0.221 0.063 0.097 0.345 0.033 0.003
Other mixed background 0.357 0.104 0.153 0.560 0.034 0.016
Asian 0.140 0.032 0.076 0.204 0.037 0.003
Other background 0.246 0.096 0.059 0.433 0.022 0.003
20k to 40k −0.112 0.021 −0.154 −0.070 −0.055 0.003
41k to 60k −0.249 0.024 −0.295 −0.203 −0.100 0.003
>60k −0.301 0.025 −0.350 −0.252 −0.119 0.003
Prefer not to say income −0.072 0.036 −0.141 −0.002 −0.017 0.450
Gender −0.002 0.015 −0.032 0.028 −0.001 1.000
(Relative) total effect
Indirect effects and direct effects 1.011 0.194 0.630 1.392 −0.325 0.003
CI, confidence intervals; S.E., standard error.
aMonte Carlo CI. Reference group for ethnicity: White. Reference group for income: less than 20k. Adjusted p values using the Holm method.
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positive for a specific phobia were more likely to be hesitant (830/
3754; 22.1%) on the survey opening hesitancy item (scoring 3, 4 or
5) than those screening negative for a specific phobia (1245/10 784;
11.5%), odds ratio = 2.18, 95% CI 1.97–2.40, p < 0.001.
Explaining vaccine hesitancy and demographic associations
Mediation analysis using SEM was used to investigate the hypoth-
esis that fear of injection partially mediates the effect of demo-
graphic associations on vaccine hesitancy. Hence, we tested a
mediational model under the SEM framework consisting of age,
gender, ethnicity and income. The sample size used in the analysis
was n = 14 149. Participants who had missing data from the demo-
graphic variables and those who selected ‘other’ for gender (n = 32)
were excluded. We also combined groups within ethnicity and
income to increase the sample size at a group level. A breakdown
of the demographic information is presented in Table 2.
The mediation results are reported in Table 3. According to
the mediation model, while holding demographic information
constant, participants with a fear of injection had higher levels
of vaccine hesitancy (B = 0.20, adjusted p < 0.01). The mediation
model indicated that gender was not a significant predictor of
fear of injection and vaccine hesitancy after controlling for age,
ethnicity and income. Thus, further mediation analysis for gender
was not conducted.
Age was a significant predictor of fear of injection (B =−0.015,
adjusted p < 0.01) and the indirect effect of age and vaccine hesitancy
via fear of injection was also found to be significant (B =−0.003,
adjusted p < 0.01). Age remained a significant predictor of vaccine
hesitancy after controlling for fear of injection (mediator), indicating
a partial mediation (B =−0.013, adjusted p < 0.01).
The mediation for ethnicity indicated that relative to White
ethnicity, only Black and Asian ethnicities were significant predic-
tors of fear of injection (B = 0.208, adjusted p < 0.01; B = 0.168,
adjusted p < 0.01). The relative indirect effects between ethnicity
and vaccine hesitancy via fear of injection were also found to be
significant only for Black and Asian ethnicities (B = 0.042,
adjusted p < 0.01; B = 0.034, adjusted p < 0.01). The relative direct
effects between ethnicity and vaccine hesitancy remained signifi-
cant for Black and Asian ethnicities (B = 0.70, adjusted p < 0.01;
B = 0.14, adjusted p < 0.01) after controlling for the fear of injec-
tion, indicating a partial mediation for these ethnic groups.
Relative to White ethnicity, White other, Other mixed back-
ground and Other ethnic groups were also associated with higher
levels of vaccine hesitancy (B = 0.22, adjusted p < 0.01; B = 0.36,
adjusted p < 0.05; B = 0.25, adjusted p < 0.01), but the relation-
ships between these ethnic groups and vaccine hesitancy were
not (partially) mediated by fear of injection.
Relative to the income group with less than £20k, only those in
the greater than £60k income group was a significant predictor of
fear of injection (B =−0.096, adjusted p < 0.01). The relative indir-
ect effect between those in the greater than £60k income group
and vaccine hesitancy via fear of injection was also significant
(B =−0.02, adjusted p < 0.01). The relative direct effect for the
Fig. 1. Mediational model using SEM for demographic associations with vaccine hesitancy. FOI, fear of injection; VAC.HES, vaccine hesitancy; ETH.B, Black ethnicity;
ETH.WO, White other ethnicity; ETH.OM, other mixed background ethnicity; ETH.A, Asian ethnicity; ETH.O, other ethnicity; INC.2040, income group between £20k
and £40k; INC.4060, income group between £40k and £60k; INC.G60, income group greater than £60k; INC.PNTS, prefer not to say income group. Reference group
for ethnicity is White. Reference group for gender is male.
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greater than £60k income group remained significant (B = −0.30,
adjusted p < 0.01) after controlling for the fear of injection, indi-
cating a partial mediation. Relative to the less than £20k income
group, those in the £20k to £40k and £41k to £60k income groups
were associated with lower levels of vaccine hesitancy (B = −0.11,
adjusted p < 0.01; B =−0.25, adjusted p < 0.01), but the relation-
ships were not (partially) mediated by fear of injection. The rela-
tive direct effects for those in the Prefer not to say income group
were not significant for both vaccine hesitancy and fear of injec-
tion. Thus, further mediation analysis for the Prefer not to say
income group was not necessary. The total effect combining all
(relative) direct and indirect effects was significant (B = 1.011,
adjusted p < 0.01). Approximately 16.1% (R2 = 0.161) of the vari-
ance in vaccine hesitancy was accounted for by the demographic
variables in the mediation model. The model showed an excellent
fit (χ2 = 2701.92, df = 142, p < 0.001, RMSEA = 0.04, SRMR =
0.01, CFI = 0.98, TLI = 0.97). Figure 1 presents the mediational
model using SEM.
Population attributable fraction
The PAF analysis was conducted based on a sample size of n = 13
875 after removing participants who answered ‘don’t know’ to the
initial vaccine hesitancy item and those with missing responses to
the demographics information, including those who answered
‘other’ to gender. According to the logistic model, the log of the
odds of people being vaccine hesitant was positively related to
the presence of blood-injury-injection phobia (B = 0.44, S.E. =
0.06, 95% CI 0.33–0.55, p < 0.001). The odds for participants
with a blood-injection-injury phobia being vaccine hesitant
were 1.55 ( = e0.4409) times greater than the odds for participants
with no blood-injection-injury phobia. The estimated PAF indi-
cated that approximately 11.5% of all participants who are vaccine
hesitant might have been prevented if fear of injection was absent
(AF = 0.1149; S.E. = 0.02, 95% CI 0.09–0.14, p < 0.001). The odds
ratios for different factors associated with vaccine hesitancy are
summarised in a forest plot generated from a single model that
contained all factors (see Fig. 2).
Discussion
Blood-injection-injury fears are remarkably common in the UK
adult general population. Our findings clearly show that these
fears have a small to medium association with COVID-19 vaccine
hesitancy. Approximately 5% of variance in COVID-19 hesitancy
scores across the adult population may be accounted for by injec-
tion fears. At an individual level, screening positive for a
blood-injection-injury phobia doubles the odds of also reporting
COVID-19 vaccine hesitancy. Around a quarter of the population
screen positive for potentially having such a phobia. A PAF calcu-
lation indicated that if blood-injection-injury phobia were elimi-
nated, then just over 10% of instances of people who are
COVID-19 vaccine hesitant might also be removed. It was also
found that two demographic factors repeatedly found to be
Fig. 2. Forest plot of associations with vaccine hesitancy (all factors included in the same model). Reference group for gender is male and for ethnicity is White.
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associated with vaccine hesitancy (age and ethnicity) were
explained to a small degree by higher levels of injection fears in
these groups. Overall, the results indicate that fear of injection
may have a small role to play in the occurrence of vaccine hesi-
tancy in adults. It is a highly plausible causal connection, and
one which we find is voiced by individuals who are vaccine hesi-
tant. However, the key caveat of this study is that all the analyses
were correlational, and causation cannot be determined. Only
future studies that lessen fears of injection and test effects on vac-
cine hesitancy can determine causation with certainty.
Our survey used a non-probability online quota sampling
method, which will have introduced bias into who was
approached to take part, and hence caution is required particu-
larly for prevalence estimates. Injection fears will also be higher
in children. Given the plausible causal connection, however, in
our view the study findings indicate that injection fears should
be addressed in vaccination programmes. The fewer the barriers
to vaccine acceptance, the more successful the programme. Fear
of injection is likely to be a barrier for some individuals but it
can be addressed in a number of ways. First, alternative needle-
free delivery routes of COVID-19 vaccination could be made
available. For example, there has been a nasal spray developed
for childhood flu and oral vaccines developed for rotavirus and
for polio. Second, administration of the vaccine by injection
could be made more tolerable, producing positive narratives in
the general public of the process. For example, looking away
from the injection may reduce fear (Mithal et al., 2018). Pain miti-
gation strategies (e.g. acute exercise) may also be helpful (Edwards
& Booy, 2019). Third, there could be wider provision of the brief
psychological treatments (exposure therapy and applied tension)
for blood-injection-injury fears that show large treatment effects
(Ayala, Meuret, & Ritz, 2009; Hiermeier & Mofrad, 2020;
McMurtry et al., 2016). The success of vital COVID-19 vaccin-
ation programmes is dependent on uptake. As such, we should
not underestimate the importance of making the thought of the
jab less anxiety-provoking for the millions of people who are
fearful of injections.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291721002609.
Acknowledgements. The study was jointly funded by the NIHR Oxford
Biomedical Research Centre (IS-BRC-1215-20008) and NIHR Oxford Health
Biomedical Research Centre (BRC-1215-20005). Daniel Freeman is a
National Institute for Health Research (NIHR) Senior Investigator. The
views expressed are those of the authors and not necessarily those of the
National Health Service, NIHR or the Department of Health and Social
Care. Stephan Lewandowsky received funding from the European Union’s
Horizon 2020 research and innovation programme under grant agreement
No. 964728 (JITSUVAX). Felicity Waite is funded by a Wellcome Trust
Clinical Doctoral Fellowship (102176/B/13/Z).
Conflict of interest. AJP is Chair of UK Dept. Health and Social Care’s
(DHSC) Joint Committee on Vaccination & Immunisation (JCVI), but does
not participate in discussions on COVID-19 vaccines, and is a member of the
WHO’s SAGE. The views expressed in this paper do not necessarily represent
the views of DHSC, JCVI or WHO. Oxford University has entered into a part-
nership with Astra Zeneca for the development of a coronavirus vaccine.
References
American Psychiatric Association (2013). Diagnostic and statistical manual of
mental disorders (5th ed.). Washington, DC: American Psychiatric
Publishing.
Ayala, E. S., Meuret, A. E., & Ritz, T. (2009). Treatments for blood-injury-
injection phobia. Journal of Psychiatric Research, 43, 1235–1242.
Dahlqwist, E., Zetterqvist, J., Pawitan, Y., & Sjölander, A. (2016). Model-based
estimation of the attributable fraction for cross-sectional, case–control and
cohort studies using the R package AF. European Journal of Epidemiology,
31, 575–582.
Edwards, K. M., & Booy, R. (2019). Pain control at the vaccine injection site:
New insights. International Journal of Travel Medicine, 26(6), taz053.
https://doi.org/10.1093/jtm/taz053.
Enders, C. K. (2001). The impact of nonnormality on full information
maximum-likelihood estimation for structural equation models with miss-
ing data. Psychological Methods, 6, 352.
Enders, C. K., & Bandalos, D. L. (2001). The relative performance of full infor-
mation maximum likelihood estimation for missing data in structural equa-
tion models. Structural Equation Modeling, 8, 430–457.
Fornell, C. (1983). Issues in the application of covariance structure analysis: A
comment. Journal of Consumer Research, 9(4), 443–448.
Freeman, D., Loe, B. S., Chadwick, A., Vaccari, C., Waite, F., Rosebrock, L., …
Lambe, S. (2020). COVID-19 vaccine hesitancy in the UK: The Oxford
Coronavirus Explanations, Attitudes, and Narratives Survey (OCEANS)
II. Psychological Medicine. https://doi.org/10.1017/S0033291720005188.
Freeman, D., Loe, B. S., Yu, L.-M., Freeman, J., Chadwick, A., Vaccari, C., …
Lambe, S. (2021). Effects of different types of written vaccination informa-
tion on COVID-19 vaccine hesitancy in the UK (OCEANS-III): A single-
blind, parallel-group, randomised controlled trial. Lancet Public Health, 6,
e416–e427.
Gerbing, D. W., & Anderson, J. C. (1984). On the meaning of within-
factor correlated measurement errors. Journal of Consumer Research, 11,
572–580.
Greenland, S., & Drescher, K. (1993). Maximum likelihood estimation of the
attributable fraction from logistic models. Biometrics, 49, 865–872.
Gunzler, D., Chen, T., Wu, P., & Zhang, H. (2013). Introduction to mediation
analysis with structural equation modeling. Shanghai Archives of Psychiatry,
25, 390.
Hiermeier, U. M., & Mofrad, L. (2020). Feasibility of one-session treatment for
specific needle phobia in an adult IAPT service – A case series. The
Cognitive Behaviour Therapist, 13, e51.
Holm, S. (1979). A simple sequentially rejective multiple test procedure.
Scandinavian Journal of Statistics, 6, 65–70.
Hu, L., & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance
structure analysis: Conventional criteria versus new alternatives. Structural
Equation Modeling, 6, 1–55.
Johnson, D. R., Nichol, K., & Lipczynski, K. (2008). Barriers to adult immun-
ization. American Journal of Medicine, 121(S2), s280s35.
Jorgensen, T. D., Pornprasertmanit, S., Schoemann, A. M., & Rosseel, Y. (2020).
semTools: useful tools for structural equation modeling. R package version
0.5-3. Retrieved from https://CRAN.R-project.org/package=semTools.
Kendler, K., Aggen, S., Werner, M., & Fried, E. (2020). A topography of
21 phobic fears: Network analysis in an epidemiological sample of adult
twins. Psychological Medicine. doi: https://doi.org/10.1017/S003329172000
4493.
Kline, R. B. (2015). Principles and practice of structural equation modeling.
New York: Guilford Publications.
Kline, T. (2005). Psychological testing: A practical approach to design and evalu-
ation. Thousand Oaks, CA: Sage.
Levin, M. L. (1953). The occurrence of lung cancer in man. Acta-Unio
Internationalis Contra Cancrum, 9, 531–541.
Little, R. J., & Rubin, D. B. . (2019). Statistical analysis with missing data (Vol.
793). New Jersey: John Wiley & Sons.
Loken, E., Hettema, J., Aggen, A., & Kendler, K. (2014). The structure of gen-
etic and environmental risk factors for fears and phobias. Psychological
Medicine, 44, 2375–2384.
MacKinnon, D. P., Lockwood, C. M., & Williams, J. (2004). Confidence limits
for the indirect effect: Distribution of the product and resampling methods.
Multivariate Behavioral Research, 39, 99–128.
McMurtry, C. M., Taddio, A., Noel, M., Antony, M. M., Chambers, C. T.,
Asmundson, G. J. G., … Scott, J. (2016). Exposure-based interventions
for the management of needle fear across the lifespan: A clinical practice
10 Daniel Freeman et al.
guideline and call for further research. Cognitive Behaviour Therapy, 45,
217–235.
Mithal, P., Simmons, P., Cornelissen, T., Wong, H., Riddell, R. P., McMurtry,
C. M., … Taddio, A. (2018). To look or not to look during vaccination: A
pilot randomized trial. Canadian Journal of Pain, 2, 1–8. https://doi.org/10.
1080/24740527.2017.1412254.
Muris, P., Schmidt, H., & Merckelbach, H. (1999). The structure of specific
phobia symptoms among children and adolescents. Behaviour Research
and Therapy, 37, 863–868.
Nikolovski, J., Koldijk, M., Weverling, G. J., Spertus, J., Turakhia, M., Saxon, L.,
… Navar, A.-M. (2021). Factors indicating intention to vaccinate with
a COVID-19 vaccine among older U.S. Adults. PLoS ONE, 16(5), e0251963.
Olatunji, B., Ebesutani, C., Sawchuk, C., McKay, D., Lohr, J., & Kleinknecht, R.
(2012). Development and initial validation of the Medical Fear Survey–
Short Version. Assessment, 19, 318–336.
Ovanessian, M., Fairbrother, N., Vorstenbosch, V., McCabe, R., Rowa, K., &
Antony, M. (2019). Psychometric properties and clinical utility of the spe-
cific phobia questionnaire in an anxiety disorders sample. Journal of
Psychopathology and Behavioral Assessment, 41, 36–52.
Poole, C. (2015). A history of the population attributable fraction and related
measures. Annals of Epidemiology, 25, 147–154.
Rosseel, Y. (2012). Lavaan: An R package for structural equation modeling and
more. Version 0.5-12 (BETA). Journal of Statistical Software, 48, 1–36.
Rubin, D. B. (1976). Inference and missing data. Biometrika, 63, 581–592.
Ruiz, J., & Bell, R. (2021). Predictors of intention to vaccinate against
COVID-19. Vaccine, 39, 1080–1086.
Saris, W. E., Krosnick, J. A., Revilla, M., & Shae, E. M. (2010). Comparing
questions with agree/disagree response options to questions with item-
specific response options. Survey Research Methods, 4, 61–79.
Sjölander, A., & Vansteelandt, S. (2011). Doubly robust estimation of attribut-
able fractions. Biostatistics (Oxford, England), 12, 112–121.
Sörbom, D. (1989). Model modification. Psychometrika, 54(3), 371–384.
Stinson, F., Dawson, D., Chou, S. P., Smith, S., Goldstein, R., Ruan, W. J., &
Grant, B. (2007). The epidemiology of DSM-IV specific phobia in the
USA: Results from the National Epidemiologic Survey on Alcohol and
Related Conditions. Psychological Medicine, 37, 1047–1059.
Taddio, A., Ipp, M., Thivakaran, S., Jamal, A., Parikh, C., Smart, S., Sovran, J.,…
Katz, J. (2012). Survey of the prevalence of immunization non-compliance
due to needle fears in children and adults. Vaccine, 30, 4807–4812.
Van Houtem, C. M. H. H., Laine, M. L., Boomsma, D. I., Ligthart, L., van Wijk,
A. J., & De Jongh, A. (2013). A review and meta-analysis of the heritability
of specific phobia subtypes and corresponding fears. Journal of Anxiety
Disorders, 27, 379–388.
Wardenaar, K. J., Lim, C. C. W., Al-Hamzawi, A. O., Alonso, J., Andrade, L.
H., Benjet, C., … De Jonge, P. (2017). The cross-national epidemiology of
specific phobia in the World Mental Health Surveys. Psychological
Medicine, 47, 1744–1760.
Wenzel, A., & Holt, C. (2003). Validation of the multidimensional blood/
injury phobia inventory: Evidence for a unitary construct. Journal of
Psychopathology and Behavioral Assessment, 25, 203–211.
Yaqub, O., Castle-Clarke, S., Sevdalis, N., & Chataway, J. (2014). Attitudes to
vaccination. Social Science and Medicine, 112, 1–11.
Psychological Medicine 11
